These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

474 related items for PubMed ID: 17161355

  • 41. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial.
    Alberú J, Pascoe MD, Campistol JM, Schena FP, Rial Mdel C, Polinsky M, Neylan JF, Korth-Bradley J, Goldberg-Alberts R, Maller ES, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2011 Aug 15; 92(3):303-10. PubMed ID: 21792049
    [Abstract] [Full Text] [Related]

  • 42. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats.
    Lloberas N, Torras J, Alperovich G, Cruzado JM, Giménez-Bonafé P, Herrero-Fresneda I, Franquesa Ml, Rama I, Grinyó JM.
    Nephrol Dial Transplant; 2008 Oct 15; 23(10):3111-9. PubMed ID: 18469305
    [Abstract] [Full Text] [Related]

  • 43. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
    Pretagostini R, Cinti P, Lai Q, Poli L, Berloco PB.
    Transpl Immunol; 2008 Nov 15; 20(1-2):3-5. PubMed ID: 18773959
    [Abstract] [Full Text] [Related]

  • 44. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
    Watson CJ, Gimson AE, Alexander GJ, Allison ME, Gibbs P, Smith JC, Palmer CR, Bradley JA.
    Liver Transpl; 2007 Dec 15; 13(12):1694-702. PubMed ID: 18044728
    [Abstract] [Full Text] [Related]

  • 45. Freedom from graft vessel disease in heart and combined heart- and kidney-transplanted patients treated with tacrolimus-based immunosuppression.
    Groetzner J, Kaczmarek I, Mueller M, Huber S, Deutsch A, Daebritz S, Arbogast H, Meiser B, Reichart B.
    J Heart Lung Transplant; 2005 Nov 15; 24(11):1787-92. PubMed ID: 16297783
    [Abstract] [Full Text] [Related]

  • 46. Sirolimus as primary immunosuppression is associated with improved coronary vasomotor function compared with calcineurin inhibitors in stable cardiac transplant recipients.
    Raichlin E, Prasad A, Kremers WK, Edwards BS, Rihal CS, Lerman A, Kushwaha SS.
    Eur Heart J; 2009 Jun 15; 30(11):1356-63. PubMed ID: 19383734
    [Abstract] [Full Text] [Related]

  • 47. Immunosuppressive agents mediate reduced allostimulatory properties of myeloid-derived dendritic cells despite induction of divergent molecular phenotypes.
    Duperrier K, Velten FW, Bohlender J, Demory A, Metharom P, Goerdt S.
    Mol Immunol; 2005 Aug 15; 42(12):1531-40. PubMed ID: 15950746
    [Abstract] [Full Text] [Related]

  • 48. Rapamycin-conditioned, alloantigen-pulsed dendritic cells promote indefinite survival of vascularized skin allografts in association with T regulatory cell expansion.
    Horibe EK, Sacks J, Unadkat J, Raimondi G, Wang Z, Ikeguchi R, Marsteller D, Ferreira LM, Thomson AW, Lee WP, Feili-Hariri M.
    Transpl Immunol; 2008 Feb 15; 18(4):307-18. PubMed ID: 18158116
    [Abstract] [Full Text] [Related]

  • 49. Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate.
    Arora S, Gude E, Sigurdardottir V, Mortensen SA, Eiskjær H, Riise G, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Aukrust P, Solbu D, Iversen M, Gullestad L.
    J Heart Lung Transplant; 2012 Mar 15; 31(3):259-65. PubMed ID: 22333403
    [Abstract] [Full Text] [Related]

  • 50. Therapeutic monitoring of calcineurin inhibitors for the nephrologist.
    Schiff J, Cole E, Cantarovich M.
    Clin J Am Soc Nephrol; 2007 Mar 15; 2(2):374-84. PubMed ID: 17699437
    [Abstract] [Full Text] [Related]

  • 51. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
    Shenoy S, Hardinger KL, Crippin J, Korenblat K, Lisker-Melman M, Lowell JA, Chapman W.
    Liver Transpl; 2008 Feb 15; 14(2):173-80. PubMed ID: 18236391
    [Abstract] [Full Text] [Related]

  • 52. Everolimus in lung transplantation in Chile.
    Parada MT, Alba A, Sepúlveda C.
    Transplant Proc; 2010 Feb 15; 42(1):328-30. PubMed ID: 20172343
    [Abstract] [Full Text] [Related]

  • 53. Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement.
    Lang UE, Heger J, Willbring M, Domula M, Matschke K, Tugtekin SM.
    Transplant Proc; 2009 Dec 15; 41(10):4285-8. PubMed ID: 20005385
    [Abstract] [Full Text] [Related]

  • 54. A novel approach to managing variation: outpatient therapeutic monitoring of calcineurin inhibitor blood levels in liver transplant recipients.
    Bucuvalas JC, Ryckman FC, Arya G, Andrew B, Lesko A, Cole CR, James B, Kotagal U.
    J Pediatr; 2005 Jun 15; 146(6):744-50. PubMed ID: 15973310
    [Abstract] [Full Text] [Related]

  • 55. Quantitative analysis of regulatory T cells in kidney graft recipients: a relationship with calcineurin inhibitor level.
    Calvo-Turrubiartes M, Romano-Moreno S, García-Hernández M, Chevaile-Ramos JA, Layseca-Espinosa E, González-Amaro R, Portales-Pérez D.
    Transpl Immunol; 2009 May 15; 21(1):43-9. PubMed ID: 19233271
    [Abstract] [Full Text] [Related]

  • 56. Calcineurin inhibitor substitution with sirolimus vs. reduced-dose calcineurin inhibitor plus sirolimus is associated with improved renal dysfunction in heart transplant patients.
    Potter BJ, Giannetti N, Edwardes MD, Cecere R, Cantarovich M.
    Clin Transplant; 2007 May 15; 21(3):305-8. PubMed ID: 17488377
    [Abstract] [Full Text] [Related]

  • 57. Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity.
    Hoerning A, Wilde B, Wang J, Tebbe B, Jing L, Wang X, Jian F, Zhu J, Dolff S, Kribben A, Hoyer PF, Witzke O.
    Transplantation; 2015 Jan 15; 99(1):210-9. PubMed ID: 25099702
    [Abstract] [Full Text] [Related]

  • 58. Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients.
    Seckinger J, Sommerer C, Hinkel UP, Hoffmann O, Zeier M, Schwenger V.
    J Hypertens; 2008 Nov 15; 26(11):2213-9. PubMed ID: 18854763
    [Abstract] [Full Text] [Related]

  • 59. [Cytofluorimetric evaluation of peripheral blood dendritic cells in patients with Mediterranean Kaposi's sarcoma].
    Vaccari M, Della Bella S, Brambilla L, Ferrucci S, Nicola S, Berti E, Boneschi V, Villa ML.
    Minerva Med; 2003 Dec 15; 94(6):379-86. PubMed ID: 14976466
    [Abstract] [Full Text] [Related]

  • 60. Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction.
    Gustafsson F, Ross HJ, Delgado MS, Bernabeo G, Delgado DH.
    J Heart Lung Transplant; 2007 Oct 15; 26(10):998-1003. PubMed ID: 17919619
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.